Inhibrx Files For IPO
socalTECH
JUNE 4, 2019
The company reported a net loss of $31.02M in 2018 on revenues of $8.5M; the company's current revenue stream includes both license fees and grants. Inhibrx develops protein engineering technology used in biopharmaceuticals research. Inhibrx is backed by LAV Biosciences Fund and Viking Global Investors. READ MORE>>.
Let's personalize your content